Charles Schwab Investment Management Inc. Acquires 11,999 Shares of Henry Schein, Inc. $HSIC

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Henry Schein, Inc. to 1,203,676 shares, valued at approximately $82.44 million, after purchasing an additional 11,999 shares during the first quarter.
• Analysts have set a consensus price target of $75.58 for Henry Schein, with ratings varying from "hold" to "buy" among different firms.
• Henry Schein reported earnings of $1.10 per share for the last quarter, missing expectations of $1.19, while revenues were slightly above consensus at $3.24 billion.

Charles Schwab Investment Management Inc. lifted its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 1.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,203,676 shares of the company's stock after buying an additional 11,999 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.98% of Henry Schein worth $82,440,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Guggenheim Capital LLC increased its holdings in shares of Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after acquiring an additional 159 shares in the last quarter. UMB Bank n.a. increased its stake in Henry Schein by 23.2% during the 1st quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock valued at $73,000 after purchasing an additional 201 shares in the last quarter. Humankind Investments LLC increased its holdings in shares of Henry Schein by 7.4% in the fourth quarter. Humankind Investments LLC now owns 3,057 shares of the company's stock valued at $212,000 after purchasing an additional 211 shares during the period. HB Wealth Management LLC increased its holdings in shares of Henry Schein by 1.5% in the first quarter. HB Wealth Management LLC now owns 15,419 shares of the company's stock valued at $1,056,000 after purchasing an additional 226 shares during the period. Finally, J. Safra Sarasin Holding AG grew its holdings in Henry Schein by 1.1% during the fourth quarter. J. Safra Sarasin Holding AG now owns 22,098 shares of the company's stock worth $1,529,000 after acquiring an additional 231 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Stock Performance

Henry Schein stock traded down $0.09 on Monday, hitting $67.76. The company's stock had a trading volume of 315,754 shares, compared to its average volume of 1,767,220. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The firm has a market cap of $8.22 billion, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 2.24 and a beta of 0.81. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The company has a fifty day moving average price of $70.81 and a 200-day moving average price of $70.72.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the company posted $1.23 EPS. The firm's revenue for the quarter was up 3.3% on a year-over-year basis. On average, equities analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Evercore ISI dropped their price objective on Henry Schein from $78.00 to $70.00 and set an "in-line" rating on the stock in a report on Wednesday, August 6th. Barrington Research reduced their price target on shares of Henry Schein from $86.00 to $78.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th. UBS Group reduced their price objective on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Stifel Nicolaus reissued a "hold" rating and set a $75.00 price objective (down previously from $80.00) on shares of Henry Schein in a report on Friday, July 25th. Finally, Robert W. Baird reaffirmed a "neutral" rating and issued a $72.00 target price (down from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $75.58.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.